ZielBio, Inc., a Charlottesville, VA-based early-stage biotechnology company that identifies novel high value disease targets and develops therapeutic interventions to improve patient outcomes, closed a $25.1m Series A financing round.
The round was led by Morningside Venture Investments and Partners Innovation Fund (PIF). In connection with the financing, PIF Partner Meredith Fisher, PhD, and Jason Dinges, JD, PhD, Investment Advisor at Morningside Technology Advisory, have joined the ZielBio Board of Directors.
The company intends to use the funds to conduct further research to prioritize potential cancer applications, validate additional targets and initiate a planned phase 1 clinical trial with ZB131.
Led by Kimberly Kelly, PhD, President and Chief Science Officer, ZielBio is an early-stage biotechnology company that identifies novel disease targets and develops therapeutic interventions to improve patient outcomes. Its proprietary drug discovery platform Zielfind™ combines functional, high throughput screening with large content data analytics to identify high value targets.
The company has a pipeline of therapies and targets, including lead compound ZB131, a proprietary humanized monoclonal antibody against cell surface plectin (CSP), a cancer target identified through Zielfind™.